True North Advisors’s Novartis NVS Stock Holding History

True North Advisors’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,368	Closed	-$547K	–	211
2023 Q3	$547K	Sell	5,368 -5,431	-50%	-$551K	0.17%	105
2023 Q2	$1.09M	Sell	10,799 -5,283	-33%	-$528K	0.31%	60
2023 Q1	$1.48M	Buy	16,082 +181	+1%	+$15.8K	0.44%	55
2022 Q4	$1.44M	Hold	15,901	–	–	0.49%	54
2022 Q3	$1.21M	Sell	15,901 -912	-5%	-$75.6K	0.4%	65
2022 Q2	$1.42M	Buy	16,813 +637	+4%	+$55.9K	0.44%	57
2022 Q1	$1.42M	Sell	16,176 -1,614	-9%	-$140K	0.38%	60
2021 Q4	$1.56M	Buy	17,790 +2,139	+14%	+$178K	0.26%	81
2021 Q3	$1.28M	Buy	15,651 +1,471	+10%	+$132K	0.25%	87
2021 Q2	$1.29M	Buy	14,180 +17	+0.1%	+$1.51K	0.27%	81
2021 Q1	$1.21M	Hold	14,163	–	–	0.29%	76
2020 Q4	$1.34M	Sell	14,163 -862	-6%	-$75.3K	0.34%	66
2020 Q3	$1.31M	Buy	15,025 +637	+4%	+$55.2K	0.38%	60
2020 Q2	$1.26M	Buy	+14,388	New	+$1.24M	0.3%	65

Other funds holding NVS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

True North Advisors's NVS Position: Q4 2023 in Review

True North Advisors sold out of Novartis (NVS) in Q4 2023, closing a stake of 5,368 shares — an estimated $547K sold.

True North Advisors first reported a position in NVS in Q2 2020 and held it in 14 quarters. The position peaked at $1.56M in Q4 2021. 1,272 funds tracked by Wall St. Rank hold NVS as of Q4 2023.

True North Advisors reported no remaining Novartis position as of Q4 2023 after selling out during the quarter.
True North Advisors sold 5,368 Novartis shares in Q4 2023, an estimated $547K.
True North Advisors first reported a position in Novartis in Q2 2020 and held it in 14 quarters.
True North Advisors's Novartis position peaked at $1.56M in Q4 2021.
1,272 funds tracked by Wall St. Rank held Novartis as of Q4 2023.

Based on True North Advisors's 13F filing for Q4 2023, filed 22 Jan 2024.